Liu, Hui
Xu, Jian-Wei
Xu, Qi-Zhang
Zeng, Yi-Rou
Funding for this research was provided by:
The National Natural Science Foundation of China (81560543 and 81673113)
Article History
Received: 20 September 2017
Accepted: 17 April 2018
First Online: 27 April 2018
Ethics approval and consent to participate
: The investigation was approved by Department of Health, Shan Special Region II, Myanmar. Ethical approval for the study under “The therapeutic efficacy study of anti-malarial drugs in the GMS” (Reference number: YIPD-EC-2007[01]) was granted by the Ethics Committees of the Yunnan Institute of Parasitic Diseases, China. According to the World Medical Association Declaration of Helsinki, the purpose of the study was explained to the study participants. Informed written consent was obtained from all adult subjects or caretakers of children. All participants (adults and guardians for children) consent to report their data. However, all results were kept confidential and were unlinked to any identifying information.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.